Vera Therapeutics, Inc. (NASDAQ:VERA) Receives $81.15 Consensus Target Price from Analysts

Posted by Brian Himes on Aug 24th, 2026

Shares of Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) have been given a consensus rating of “Moderate Buy” by the fourteen analysts that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, eleven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $81.1538.

A number of brokerages have recently commented on VERA. TD Cowen boosted their price objective on shares of Vera Therapeutics from $73.00 to $78.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. HC Wainwright decreased their target price on shares of Vera Therapeutics from $125.00 to $90.00 and set a “buy” rating for the company in a research report on Wednesday, August 12th. Raymond James Financial reiterated a “strong-buy” rating and issued a $84.00 price target on shares of Vera Therapeutics in a research note on Tuesday, August 11th. Needham & Company LLC set a $125.00 price target on shares of Vera Therapeutics in a research report on Wednesday, July 8th. Finally, Wedbush reissued a “neutral” rating and set a $34.00 price target on shares of Vera Therapeutics in a research report on Monday, August 17th.

Check Out Our Latest Stock Analysis on VERA

Vera Therapeutics Stock Performance

NASDAQ VERA opened at $32.28 on Wednesday. The stock has a market capitalization of $2.33 billion, a price-to-earnings ratio of -5.51 and a beta of 0.92. The stock’s 50 day moving average price is $36.32 and its two-hundred day moving average price is $37.99. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.92 and a current ratio of 10.92. Vera Therapeutics has a 52 week low of $21.15 and a 52 week high of $56.05.

Vera Therapeutics (NASDAQ:VERA – Get Free Report) last released its quarterly earnings results on Monday, August 10th. The company reported ($1.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.58) by $0.06. During the same period last year, the company posted ($1.20) EPS. As a group, analysts anticipate that Vera Therapeutics will post -6.43 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Marshall Fordyce sold 46,250 shares of Vera Therapeutics stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $42.30, for a total value of $1,956,375.00. Following the sale, the chief executive officer owned 151,994 shares of the company’s stock, valued at approximately $6,429,346.20. The trade was a 23.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 15.90% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Readystate Asset Management LP acquired a new position in shares of Vera Therapeutics during the 2nd quarter worth approximately $12,663,000. Odyssean LLC raised its stake in shares of Vera Therapeutics by 192.6% during the 2nd quarter. Odyssean LLC now owns 60,005 shares of the company’s stock worth $2,575,000 after purchasing an additional 39,495 shares in the last quarter. Braidwell LP boosted its holdings in shares of Vera Therapeutics by 7.8% in the 2nd quarter. Braidwell LP now owns 564,724 shares of the company’s stock valued at $24,232,000 after buying an additional 40,900 shares during the last quarter. Nykredit A S acquired a new stake in shares of Vera Therapeutics in the 2nd quarter valued at approximately $97,000. Finally, NINE MASTS CAPITAL Ltd bought a new position in shares of Vera Therapeutics in the second quarter valued at $405,000. 99.21% of the stock is currently owned by institutional investors.

About Vera Therapeutics

(Get Free Report)

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.